MUC-1/WT1 Peptide-primed Autologous Dendritic Cells
muc-1/wt1 peptide-primed autologous dendritic cells
"A cell-based cancer vaccine composed of autologous monocyte-derived dendritic cells (DCs) loaded with the human tumor-associated antigens (TAAs) mucin-1 (MUC1) and Wilms tumor protein 1 (WT1), with potential immunomodulating and antineoplastic activities. Upon vaccination, the MUC-1/WT1 peptide-primed autologous DCs expose the immune system to MUC1 and WT1 peptides and may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against MUC1 and WT1-expressing cancer cells, which could result in cancer cell lysis. MUC1 and WT1, are overexpressed in a variety of tumor types and play an important role in tumor cell proliferation."